Skip to main content
. 2021 Jul 13;12(7):698. doi: 10.1038/s41419-021-03998-w

Fig. 6. Sorafenib does not cause ferroptosis in human hepatoma cell lines.

Fig. 6

a Immunoblots of xCT in WT HT1080, SLC7A11KO HT1080, and HLE, HLF, HepG2, Huh7 hepatoma cells. VCP was used as a loading control. b Cell viability of HLE, HLF, HepG2, and Huh7 cells treated with indicated concentrations of sorafenib, sulfasalazine, or erastin, in the absence or presence of 50 μM β-ME, 1 μM Lip-1, or 100 μM DFP for 24 h. Data are presented as mean ± s.d. of n = 3 wells of a 96-well plate from one representative of three independent experiments.